mdatl.com
 
vicodin online
 
News Events Profiles Clinical Management Directory
 
 
 
 

Archive for August, 2017

Kahn named medical director of radiation oncology at Winship at Emory Saint Joseph’s Hospital

Sunday, August 27th, 2017

Shannon Kahn, MD

Winship Cancer Institute (Winship) has named Shannon Kahn, MD, medical director of radiation oncology at Emory Saint Joseph’s Hospital. A board certified radiation oncologist, Kahn joined the Winship staff at Emory Saint Joseph’s five years ago and specializes in the treatment of patients with malignant and benign brain tumors, breast and lung cancers.

She is skilled at Gamma Knife radiosurgery, a minimally invasive radiation treatment for malignant and nonmalignant tumors, trigeminal neuralgia (facial pain syndrome), and other neurological disorders.

“Shannon is an extraordinary physician and has already established herself as a great leader at Winship at Emory Saint Joseph’s Hospital,” says Winship Executive Director Walter J. Curran, Jr., MD.

Prior to her career in medicine, Kahn earned her Bachelor of Science in Business Administration and a Master in Accountancy at the University of North Carolina at Chapel Hill and worked for Arthur Andersen as a certified public accountant and financial auditor. When her mother was diagnosed with breast cancer, Kahn decided to pursue a career in medicine. She earned her degree from the Emory University School of Medicine, completing her internship in internal medicine and residency in radiation oncology at Emory University.

Kahn has authored and co-authored several presentations at national research and healthcare meetings and many publications in national and international peer-reviewed journals. She has published on the use of radiotherapy for patients with Hodgkin’s and non-Hodgkin’s lymphoma, the effectiveness and side-effect profile of radiotherapy in the treatment of prostate cancer, and the use of alternative treatment modalities for long-term treatment sequelae among patients with head and neck cancer.

Kahn is a member of Winship’s Cancer Prevention and Control Research Program. Her society memberships include the American Medical Association, the American Society of Therapeutic Radiology and Oncology, and the American Society of Clinical Oncology.

Share

Paul Scheinberg, MD retires after 38-year career at Emory Saint Joseph’s Hospital

Tuesday, August 29th, 2017

Paul Scheinberg, MD, chief medical officer and chief quality officer for Emory Saint Joseph’s Hospital, has retired after a 38-year career in pulmonology.

Scheinberg built a practice and was a founding partner of Atlanta Pulmonary Group. Since 1979, he was actively engaged in the practice of pulmonology and critical care medicine at Saint Joseph’s Hospital. A self-described “clinician at heart,” Scheinberg dedicated his career to patient care, and also to mentoring many physicians. “The relationship with my patients has been so rewarding, and I have learned from all of them. I have always focused my attention on being the best physician I could be for them,” he says.

During his career at the hospital, Scheinberg received the Napier Burson Physician of Distinction award in 2013, Emory Saint Joseph’s highest honor for physician service. Scheinberg was awarded this honor based upon his adherence to the Mercy philosophy and contribution to the Mercy mission in Atlanta; his contribution to the quality of medicine practiced at Emory Saint Joseph’s; and leadership as a member of the medical staff.

In addition to serving as chief medical officer and chief quality officer at Emory Saint Joseph’s, Scheinberg’s leadership positions also included serving as chief of the medical staff, chair of the Department of Medicine and chief of the Pulmonary Section.

“We are grateful to Dr. Scheinberg for his tireless commitment to Emory Saint Joseph’s and patients in our community, and as a valued colleague, we will miss his contributions on our team,” says Heather Dexter, CEO of Emory Saint Joseph’s.

Throughout his career, Scheinberg dedicated significant time to research and served as principal investigator in numerous studies involving chronic lung disease, acute exacerbation of chronic bronchitis, pneumonia and bronchiectasis, as well as sleep disorders and smoking cessation.

Scheinberg’s first experience in the field of medicine occurred at the age of five, when he followed his physician father on rounds at Maimonides Medical Center in Brooklyn, New York. “There was never a question in my mind about becoming a doctor,” he says about following his father’s model and dedication to medicine.

Scheinberg received his medical degree from the State University of New York Downstate Medical School, and completed his internal medicine residency at Grady Memorial Hospital. During his residency, he served as a flight surgeon in the U.S. Navy, where he studied and developed an interest in pulmonary physiology. He completed his internship and residency in internal medicine at Emory University, followed by a fellowship in pulmonary diseases at Emory.

In addition to his medical career, Scheinberg has been actively involved for many years with the Jewish National Fund, establishing medical facilities in the southern area of Israel near Negev and the Jordanian border. He also established relationships with a delegation of Israeli mayors and community leaders from the Western Galilee Cluster. During a visit to Emory Saint Joseph’s last fall, Scheinberg introduced the group to various areas of medical technology and patient care.

Share

Northside Hospital offers new NETSPOT diagnostic imaging tool for the detection, staging and restaging of rare neuroendocrine tumors

Monday, August 28th, 2017

A new tool available at Northside Hospital aims to locate, stage and restage rare neuroendocrine tumors (NETs) in patients, helping doctors find disease that they were unable to see before.

More than 12,000 people in the United States are diagnosed with NETs each year, according to the Neuroendocrine Tumor Research Foundation. NETs develop in the hormone-producing cells of the body’s neuroendocrine system.

Most NETs are not harmful. They often form in the intestine, pancreas or lungs, but sometimes trigger a rare form of cancer that can be difficult to diagnose with current imaging techniques.

The Northside Hospital Cancer Institute treats more than 300 newly diagnosed cases of NETs year. The hospital is one of only a handful in the Southeast to offer NETSPOT®, a product recently approved by the U.S. Food and Drug Administration for the preparation of Gallium-68 (Ga-68) dotatate for PET/CT (positron emission tomography – computed tomography) imaging.

“NETSPOT provides a more sensitive and specific imaging tool to determine location of disease, for staging and restaging of patients with well-differentiated and moderately-differentiated NETs,” said Dr. William C. Lavely, nuclear medicine specialist at Northside Radiology Associates.

Ga-68 dotatate is a radioactive diagnostic agent that is specifically designed to detect somatostatin receptors, including those in NETs. When injected into the patient, the agent binds to the receptors.

“Somatostatin is a hormone that regulates the endocrine system and is expressed by neuroendocrine cells,” said Dr. Lavely. “This provides a unique target for neuroendocrine tumor imaging.”

Combined with PET/CT imaging, which offers higher resolution, three-dimensional and more rapid imaging than other imaging technologies, NETSPOT gives doctors a better picture of the disease and what they have to treat.

“Patients who are diagnosed with NETs early have a better chance of beating or managing the disease,” said Dr. Lavely.

NETSPOT is currently available at Northside Hospital imaging centers in Atlanta, Cumming, Decatur, Fayetteville and Lawrenceville.

Share

Glaucoma:

Wednesday, August 30th, 2017

Increasingly Common as the Population Ages but Treatment Has Never Been Better!

By Elma Chang, M.D. and Reay Brown, M.D.

Three million people in the U.S have glaucoma – an asymptomatic, blinding eye disease. At least 1 million of these victims don’t even know they have it, which is why glaucoma is called the “Thief in the Night.” Detecting glaucoma is one of the main reasons we recommend an eye exam every 1 or 2 years, even for people who feel like they are seeing very well.

The fluid inside the eye has a natural circulation designed to achieve a normal internal pressure. Normal pressure should be defined as any pressure that does not cause optic nerve damage with a corresponding visual field defect. Using this argument, the previously accepted thought that a patient cannot have glaucoma if the eye pressure is below 21 is false. In the same way, if a patient has an eye pressure above 21 but no coexisting optic nerve damage, the patient is diagnosed with ocular hypertension and not glaucoma.

In a patient where it has been established that the optic nerve has thinning that corresponds with a visual field loss, visual fields are obtained on an annual basis. Peripheral vision is slowly – and imperceptibly – lost. If undetected and untreated, the eye may become totally blind. Since glaucoma is usually bilateral, patients too often present with blindness in one eye and advanced visual loss in the other. However, this progressive damage can be slowed or stopped completely by treatments that reduce the eye pressure to a normal level.

Fortunately, we have many excellent treatments for glaucoma. Eye drops are usually the first line of treatment. These lower pressure by enhancing outflow and reducing the fluid production. The next step is laser treatment – a very safe and effective option that is performed in the office and only takes a few minutes.

Cataract surgery has been found to be a very effective intervention for lowering eye pressure even though its main goal is to improve vision. We also have several devices (iStent, CyPass, and Xen implants) that we can place at the time of cataract surgery, and these have been breakthroughs in glaucoma treatment. Patients who need further pressure lowering will receive a trabeculectomy or a tube-shunt.

Medications – Both Now and the Future

Eye drops that decrease fluid production are beta-blockers (timolol maleate, Betimol, Timoptic), adrenergic agonists (brimonidine, Alphagan) or topical and oral carbonic anhydrase inhibitors (dorzolamide, Azopt, acetazolamide, Diamox). Medicines that promote outflow are cholinergic agonists (Pilocarpine), adrenergic agonists and prostaglandin analogs (latanoprost, Lumigan, Travatan, and Xalatan).

Rhopressa is a newer topical medication that is awaiting final FDA approval and will be available soon. It acts via rhokinase inhibition. This has been found to increase both aqueous outflow through the trabecular meshwork and reduce episcleral venous pressure.

Newer Delivery Systems

Eye drops require that patients use them once or twice daily. Compliance has been a major obstacle in treating glaucoma patients. Studies have shown that as many as 80 percent of patients forget to take their eye drops. Sustained drug delivery devices may be one key to improving compliance.

One device is a ring that is placed under the upper and lower lids. Another device is placed in the tear punctum in the lower lid. These devices are in studies and have shown good results.in reducing intraocular pressure (IOP) for up to 6 months.

Other studies have examined the use of particulate drug delivery systems or injectable formulations such as microspheres, liposomes and nanospheres/nanoparticles. This involves trapping the drug in the nanocarrier matrix and releasing the bioactive agent in a controlled fashion after administration.

It is impossible to know which of these technologies will emerge as the best option, but it is clear that longer duration treatments are a critical unmet need. We will continue to see rapid improvement in these technologies.

Laser Surgery

Laser surgery has traditionally been used as an intermediate step between topical therapy and incisional surgery. Laser therapy can increase outflow of fluid through the trabecular meshwork (laser trabeculoplasty) or decrease aqueous production from the ciliary body (diode laser cyclophotocoagulation). Laser trabeculoplasty can easily be performed in the office setting.

The Micropulse laser is a newer laser technology that seeks to improve the safety of the traditional diode cyclophotocoagulation while preserving the pressure-lowering.

Cataract Surgery with MIGS

One of the major recent advances in glaucoma treatment has been the discovery that cataract surgery lowers pressure and that the magnitude of pressure reduction was proportional to the pre-op intraocular pressure. In other words, cataract surgery is also a glaucoma operation that lowers pressure best in patients who need it the most.

There are 3.5 million cataract operations each year in the U.S., and studies show that as many as 20 percent of these patients have a concurrent diagnosis of glaucoma. So, this is all very good news for glaucoma patients.

Cataract and glaucoma are also linked because the two new devices that have been approved for glaucoma treatment – the iStent and CyPass – are restricted for use only at the time of cataract surgery. They can be used “off-label” as stand-alone procedures, but insurance coverage is more uncertain.

Image 1

The iStent (Image 1) and CyPass (Image 2) are the first devices in the category of micro-incisional glaucoma surgery or MIGS. MIGS is a revolution in glaucoma treatment. MIGS approaches are much safer than conventional glaucoma surgery.

One of the key differences between MIGS and traditional glaucoma surgeries is the approach to the eye’s outflow system. Specifically, an ab interno approach is used in MIGS where the surgeon is able to access the trabecular meshwork (iStent) or suprachoroidal space (CyPass) via a corneal incision. Previously, the outflow system was approached via an ab externo approach, which meant that the outflow system was accessible only after resecting back conjuntival and scleral tissues.

There are many new approaches in the MIGS category. These include the ability to thread a catheter in the space behind the trabecular meshwork (canaloplasty) and then pull the catheter through the meshwork and creating an opening in the trabecular meshwork (goniotomy). A similar goniotomy effect can be achieved with several new technologies – the Trabectome, the Kahook blade and the Trab360 device.

Image 2

Incisional Surgeries – Now and What’s on the Horizon

In some cases, treatment with eye drops, laser, cataract surgery and MIGS may not be enough to halt glaucoma damage. The next step is a trabeculectomy or a tube implant. These procedures create a pathway – essentially a hole – from inside the eye to a bleb (a fluid-filled bump) on the ocular surface. This can achieve profound pressure reduction but has a greater risk of infection, IOP being too low for clear vision, double vision and failure.

Finally, the newest device to achieve FDA approval is the Xen gel implant. This device is also implanted ab interno via a corneal incision. It is a newer and less invasive way to perform the trabeculectomy. The goal is to implant a gel-like Xen material in the subconjunctival space. The implant itself maintains a passageway between the anterior chamber and the subconjunctival space. The hope is that this will be safer than a traditional trabeculectomy but just as effective in lowering IOP.

The pace of innovation in glaucoma treatment is accelerating – both for topical therapy and for surgery. Most glaucoma surgeons still perform traditional glaucoma surgeries (trabeculectomies and tube implantations), but the acceptance of MIGS devices and technology is growing.

Our practice has been involved with some of the research that led to the development of the iStent and with the studies that led to the approval of the CyPass. We believe that MIGS is fundamentally changing the glaucoma treatment paradigm with surgical approaches becoming more common.

But these innovations are just the beginning. We have never had so many outstanding options for treating glaucoma and tailoring the approach to each patient. No one should ever become blind from glaucoma.

 


Radcliffe NM, Lynch MG, Brown RH. Ab interno stenting procedures. J Cataract Refract Surg 2014;40:1273–1280.

Brown RH, Zhong L, Lynch, MG. Lens-based glaucoma surgery: Using cataract surgery to reduce intraocular pressure. J Cataract Refract Surg 2014;40:1255–1262.

Brown RH, Zhong L, Lynch MG. Clear lens extraction as treatment for uncontrolled primary angle-closure glaucoma. J Cataract Refract Surg 2014;40:840–841.

Brown RH, Zhong L, Whitman AL, Lynch MG, Kilgo PD, Hovis KL. Reduced intraocular pressure after cataract surgery in patients with narrow angles and chronic angle-closure glaucoma. J Cataract Refract Surg, 2014; 40:1610-1614

Brown RH, Gibson Z, Zhong L, Lynch MG. Intraocular pressure reduction after cataract surgery with implantation of a trabecular microbypass device. J Cataract Refract Surg, 2015 41: 318-319

Vold S, Ahmed IK, Craven R, Mattox C, Stamper R, Packer M, Brown RH, Ianchulev T. For the CyPass Study Group, Minimally invasive surgical treatment for glaucoma: 2-year pivotal RCT results of supraciliary microstenting. Ophthalmology 2016; 1-10.

Share

Cosmetic Applications of Lasers and Light/Energy-based Devices

Wednesday, August 30th, 2017

By Rutledge Forney, M.D.

Helping children with facial port wine stains was the first cosmetic usage of laser energy. Since then, our understanding of energy in the skin has grown exponentially.

Today, lasers and other light/energy-based devices have dozens of cosmetic applications. From hair to brown spots to wrinkles and much more, demand for non-invasive (non-surgical) procedures has exploded as the baby boomers have aged.

A laser wavelength targets and destroys a specific “chromaphore,” or colored molecule, and can focus at different levels in the skin to minimize damage. Research into tissue temperature sensitivity has brought new ways to tighten skin and “kill” fat. Cosmetic market competition is strong, so these devices have to be effective to replace surgery and older technology. This article will provide an overview and act as a primer for the reader.

Vascular Targets

Pulsed dye and KTP lasers are the gold standards for facial veins and redness. Birthmarks, rosacea, angiomas and sun damage respond well to the 532, 585 and 595 nanosecond wavelengths. Multiple manufacturers make devices with these settings, with the differences being the method of cooling the skin, spot sizes and pulse length.

Leg veins are harder to treat with lasers due to thick skin and pressure in the legs from gravity. 1064 NdYag lasers are marketed to help leg veins, but every lecture I go to on leg veins and lasers confirms that the gold standard for leg veins is still sclerotherapy.

Brown Spots

All brown spots are not created equal! Some are sun damage, some are genetic. Some are superficial, some deep. Some are from hormones, some from acne or trauma. But all brown spots are universally despised. Lasers can help some, not all, brown spots. Lasers can darken brown spots from hormones (melasma).

Many different lasers and light-based devices target brown spots. Classically, intense pulsed light (IPL) – not a laser but a spectrum of light – is used to treat an area of sun damage, principally on the face, neck, chest and arms. Over a few days, obvious and not-so-obvious brown spots disappear. Remaining brown spots may be cleaned up individually with new picosecond lasers and 810 and 1064 wavelengths lasers.

Hair Reduction

The most common use of cosmetic laser therapy today is hair reduction. Dark hair in light skin can be treated effectively. Unfortunately, light hair does not have a “chromophore” to attract a laser, and dark hair in dark skin cannot be “seen” by the laser. Hair reduction wavelengths are commonly 810 in lighter skin, 1064 in darker skin. IPL is used for hair reduction but with a higher risk of hyperpigmentation and blistering due to multiple wavelengths hitting unintended targets.

Skin Texture, Wrinkles and Collagen Refreshment

Aging, primarily sun damage, causes large pores, wrinkles/crinkles and droopy skin. Compare the skin on your lower abdomen or buttocks (which typically has less sun damage) to that of your hands or face. A biopsy of 60-year-old sun-damaged skin compared to young sun-protected skin shows frayed, crinkled collagen and increased elastin. Anyone can tell the difference.

According to The New York Times, collagen production is stimulated by three things. One: laser resurfacing, which gets energy into the dermis where most damaged collagen is found. Two: prolonged use of tretinoin. Three, dermal fillers, which are used to plump thin lips, enhance contours, soften facial creases, remove wrinkles and improve the appearance of recessed scars. Enough said.

In the 1990s, two laser wavelengths were used for full face resurfacing, CO2 and Erbium Yag. They completely removed the epidermis and tightened the dermis. Folks who got a great result were thrilled, but not all got a home run. Poor healing and infection could impair results. It was expensive and usually required general anesthesia. Patients needed to lay low for 3 weeks, keeping the face moist, covered and out of the sun until the epidermis reformed. Scarring and hypopigmentation were not uncommon. Still, the demand for improvement in aged skin motivated research into other options.

In 2005, the fractionated laser was born. It lasered 20 percent, not all of the epidermis and superficial dermis, leaving columns of lasered skin surrounded by normal skin. This assured that the lasered skin was excreted and the damage healed quickly without scarring or hypopigmentation. The original wavelength was 1550; five treatments resurfaced the face for maximum results. Fractionated lasers now include 1550, CO2 and Erbium Yag. Multiple treatments are necessary, with some downtime, but not the risks of non-fractionated lasers.

Skin Tightening

Radiofrequency and ultrasound are now used to tighten skin without surgery. Both go through the epidermis into the dermis without damaging the skin, so they have no downtime. Radiofrequency heat contracts dermal collagen while ultrasound focuses on lower levels of the dermis. Some devices add microneedles to wound the epidermis and deliver focused radiofrequency waves deeper in the skin to tighten both epidermis and dermis.

Fat Destruction and Body Sculpting

Fat is the latest frontier in noninvasive, in-office procedures. Liposuction has been used for decades to remove fat cells in localized fat pockets. Laser-assisted liposuction was developed about 15 years ago to make the process less traumatic and to tighten skin from the inside. Knowledge that fat is temperature sensitive led the developers of the fractionated laser to focus on ways to destroy fat noninvasively. A technique to freeze fat while protecting the overlying skin and underlying muscle was first approved by the FDA in 2010 and is now considered by many to be the gold standard for noninvasive fat destruction. It takes three months to see results; the tradeoff is no cuts, stitches and invasive suction, which is worth it to many.

Cold kills fat, but so do heat and ultrasound! Radiofrequency waves and focused 1064 lasers are used to heat fat. Deep ultrasound is being used to target fat pockets as well.

Tattoo Removal

Tattoo removal is challenging. It involves multiple chromophores (colors), hence multiple wave lengths. The science is that the laser hits the ink and breaks it into smaller pieces, which the body’s macrophages carry away. It typically involves multiple treatments about every 2 months, with eight to 20 total treatments necessary.

A breakthrough in tattoo removal came with the development of a picosecond laser. (All conventional cosmetic lasers are nanoseconds.) This extraordinarily fast laser adds acoustic energy, breaking ink into smaller pieces so it is removed faster, requiring only three to eight treatments.

Obviously, there are many devices and methods that improve the appearance of skin and the body. Young skin reflects light, is smooth and one color. Photo-aging results in dyschromia (multiple colors in the skin: reds and browns of multiples shades), prominent vessels, a rough texture, enlarged oil glands and folds in the skin. The skin is dull with permanent lines from smiling and frowning (motion).

The underlying problems are that collagen and blood vessel walls are damaged by sun and free radicals, and the body’s protective pigmentation eventually cannot be totally removed because the removal processes are tired and worn out.

Not every machine is right for every person. The physician directing treatment must understand the color of the skin. Though operating lasers and other cosmetic devices can be delegated, the devices discussed here require the direction of a physician.

Remember that if one only has a hammer, then everything will look like a nail. Make sure that the physician understands the patient’s goals and that the physician and the patient are sure that the treatment is right for that patient.

Share

Piedmont Healthcare to Open 27 Retail Clinics

Saturday, August 26th, 2017

Retail clinics located in 27 Walgreens stores in metro Atlanta will become an extension of Piedmont Healthcare beginning this month. Called Piedmont QuickCare at Walgreens, the retail clinics offer consumers increased access to healthcare services for minor injuries and illnesses that are not life threatening.

QuickCare Ribbon Cutting

“Our goal in opening Piedmont QuickCare locations is to make it as easy as possible for people to get the care they need, when they need it,” said Kevin Brown, CEO of Piedmont Healthcare. “We’re proud to be able to expand into these areas and provide high-quality, patient-centered care close to home for our patients.”

The retail clinics will complement Piedmont Healthcare’s existing virtual care (Piedmont OnCall), primary care and urgent care options. With extended walk-in hours and convenient online scheduling, Piedmont QuickCare at Walgreens will make it easier for consumers to take charge of their health.

“At Piedmont, we’re always looking for opportunities to improve the patient experience by making it easy to access care where and when it is the most convenient for the patient,,” Brown said. “The team at Piedmont QuickCare will be able to treat anything from aches and pains to ongoing health conditions like high blood pressure and diabetes. Plus, patients will be able to pick up medications they need onsite.”

In February, Piedmont and Walgreen announced they would form a collaborative council to share best practices and experiences aimed at improving patient care, quality and satisfaction while reducing healthcare costs. The new clinic agreement builds on an existing relationship between the two organizations that dates back to 2009.

Share

Northside Hospital and Gwinnett Health System Reach Agreement on Combining Operations

Wednesday, August 30th, 2017

Northside Hospital and Gwinnett Health System (the parent of Gwinnett Medical Center) announced that they have submitted their proposed merger agreement to the State of Georgia Office of the Attorney General for review and approval. Depending on the review process, the five-hospital Northside-Gwinnett Health combined system could be operational in early 2018.

Northside Hospital and Gwinnett Health System previously announced that they had signed a letter of intent to begin discussions to combine their operations. Both systems have taken the necessary time  to conduct this process carefully and deliberately. The primary due diligence and planning process has concluded and the systems are moving forward with the proposed merger.  

Anchored by Northside Hospital in Sandy Springs and Gwinnett Medical Center in Lawrenceville, the new health system also will include hospitals in Canton, Cumming and Duluth, as well as cancer treatment centers, imaging centers, urgent care centers and other outpatient locations throughout the state. Altogether, the Northside-Gwinnett combined system will have 1,479 beds, nearly 21,000 employees and 3,500 physicians on staff.

Share

Winship at Emory University is Now a National Cancer Institute — Designated Comprehensive Cancer Center

Tuesday, August 22nd, 2017

emory winship

Emory’s Winship Cancer Institute (Winship at Emory) has earned the comprehensive cancer center designation from the National Cancer Institute (NCI), the highest honor given to a cancer center in the United States. As the only NCI-designated cancer center in the state of Georgia, Winship at Emory is proud to be on the leading-edge of discoveries and translational research resulting in therapies improving cancer patient outcomes.  This NCI designation means that Winship at Emory has demonstrated its programs are reducing the cancer burden on the state of Georgia through research conducted in its laboratories, its clinical trials program, and its population-based science.

Outstanding Cancer Care Embedded in a Culture of Discovery 
Making a difference in Georgia and beyond, Winship at Emory evaluates and cares for over 15,000 new patients a year. It is Winship at Emory’s innovative research that translates into better ways of detecting and diagnosing cancer for all cancer patients. Patients have full access to teams of experts that specialize in specific cancer subtypes to facilitate care using treatment plans not available outside of a top research cancer center.  Disease-specific specialists work to understand the biological and genetic make-up of each individual patient’s cancer. They use the latest in precision medicine. With over 250 clinical trials, including the state’s largest stand-alone phase I unit, Winship at Emory is enrolling patients in pursuit of better approaches to every type of cancer.

The comprehensive cancer center designation recognizes that Winship researchers are studying the environmental and genetic issues unique to cancer in Georgia with the very specific goals of reducing the risk of cancer and detecting cancer at the earliest possible stage.

Unique Collaborations with National Leaders in Cancer Discovery 
Winship at Emory collaborates in cross-cutting initiatives with research institutions including the Georgia Institute of Technology, the Centers for Disease Control and Prevention, the Morehouse School of Medicine and the American Cancer Society.  Winship at Emory also serves as the coordinating center for all cancer research, education, and care for Emory Healthcare, recognized as the largest and most comprehensive academic healthcare system in Georgia, with more than 2,000 doctors and 200 locations, including 6 hospitals throughout Atlanta.

As part of an elite group of NCI-Designated Comprehensive Cancer Centers, Winship at Emory is at the forefront of establishing and incorporating the most advanced and effective cancer treatments into clinical practice globally.

Referrals for Your Cancer Patients

Cancer is complex.  Winship Cancer Institute of Emory University is capable of handling all cancers from prevalent to rare.   Give your patients access to expert teams dedicated to their specific cancer and a personalized treatment plan with innovative clinical trials. Winship at Emory is the state’s first and only NCI-Designated Comprehensive Cancer Center.

• Where patients get personalized treatments, many offered years before anywhere else.

• Teams of subspecialty experts only focus on one cancer type and develop an individualized treatment plan for cancer patients.

• Winship at Emory has been recognized as one of the nation’s best.  With over 250 active phase I, II, and III clinical trials, Winship researchers are dedicated to taking new cancer treatments from bench to bedside.

For cancer patients, the right referral can make all the difference.
Visit emoryhealthcare.org/referwinship to learn more.

 

Share

11th Annual Women and Heart Disease Conference

Saturday, August 19th, 2017
August 192017.  TWELVE Hotel Atlantic Station. Atlanta, Georgia. For more information visit, med.emory.edu 
Share

Scoliosis Screening Conference

Tuesday, August 29th, 2017

Aug. 29, 2017. For more information visit, choa.org

Share

 

 
Resources F T L Subscription Advertising About Us Past Issues Contact